MBX Biosciences, Inc.
MBX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001776111
In the last 90 days, MBX Biosciences, Inc. insiders filed 0 open-market purchases and 1 sale; 172 institutions reported holding it in 13F filings for Q2 2026, worth $3.06B in total; no superinvestor holds it.
Q1 2025 vs. Q4 2024
How the institutions holding MBX Biosciences, Inc. changed between Q4 2024 and Q1 2025.
All holders in Q1 2025All holders in Q4 2024
| Measure | Q4 2024 | Of which not filed for Q1 2025 | Q1 2025 | Change |
|---|---|---|---|---|
| Holders | 63 | 1 | 79 | +17 |
| Shares | 32.9M | 14.5K | 35.7M | +2.74M (+8.3%) |
| Value | $606.5M | $266.7K | $263.2M | −$343.0M (−56.6%) |
1 institution that held it in Q4 2024 haven't filed for Q1 2025 yet. Not filing isn't selling, so the changes leave them out.
New holders (27)
Institutions that held MBX Biosciences, Inc. at the end of Q1 2025 but not at the end of Q4 2024.
Sold out (10)
Institutions that held MBX Biosciences, Inc. at the end of Q4 2024 and filed for Q1 2025 without it.
| Institution | Shares, Q4 2024 | Value, Q4 2024 |
|---|---|---|
| Citadel Advisors LLC | 220,330 | $4.06M |
| Alyeska Investment Group, L.P. | 174,700 | $3.22M |
| Teachers Retirement System of the State of Kentucky | 26,708 | $492.0K |
| Norges Bank | 25,000 | $460.8K |
| Saturn V Capital Management LLC | 18,000 | $331.7K |
| BIT Capital GmbH | 12,743 | $234.9K |
| MetLife Investment Management | 7,230 | $133.2K |
| Sandia Investment Management LP | 5,000 | $92.2K |
| Virtus ETF Advisers LLC | 3,468 | $63.9K |
| R Squared Ltd | 400 | $7.37K |
Not filed for Q1 2025 yet (1)
Institutions that held MBX Biosciences, Inc. at the end of Q4 2024 and haven't filed a 13F for Q1 2025. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q4 2024 | Value, Q4 2024 |
|---|---|---|
| Nuveen Asset Management, LLC | 14,471 | $266.7K |